Why? Why? and why?
Did the 2024 Q1 and Q2 audited SEC
Why? Why? and why?
Did the 2024 Q1 and Q2 audited SEC filings, due in May 15th and August 15th, NOT get filled?
And Why NO AUDITED 2023 annual 10-K filed by April 15th?
And Why NOT a single 8-K filing for SPP Australia Pty Ltd importer agreement signed with GEP/Sun Group and SolRay, Inc. and NO 8-K filed for Snpw employees and representatives being promoted on a competitive solar panel and lithium battery company’s website named SolRay,Inc.and NO 8-K Subpoenas filed against the self-described bashers and trolls to prevent due diligence from being shared on message board forums.
Sun Pacific Holding Corp. (SNPW) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
iCapital Enhances Portfolio Construction Tools for Investors iCapital, a leading global fintech platform, has introduced significant enhancements to its innovative portfolio construction tool, iCapital Architect. This advanced platform is designed to simplify the integration of alternative investments into traditional portfolio strategies. Financial advisors gain access...
Continue Reading
Understanding Recent Market Movements The market experienced a turbulent session recently, sending investors into a state of caution. This volatility was significantly influenced by renewed discussions around tariffs impacting trade relationships, particularly involving technology and manufacturing sectors. The Impact of Tariffs on the Market Former President Trump's...
Continue Reading
Performance Systems Integration Merger with Summit Fire & Security Performance Systems Integration (PSI), recognized as the leading fire and life safety solutions provider in the Pacific Northwest, has completed a merger with Summit Fire & Security LLC, which is a subsidiary of SFP Holding, Inc. This merger marks a significant collaboration that aims to enhance the safety...
Continue Reading
Revealing Interim Results from Candel Therapeutics NEEDHAM, Mass. — Candel Therapeutics, Inc. (Nasdaq: CADL), a biopharmaceutical company dedicated to advancing biological immunotherapies to combat cancer, has announced noteworthy interim data stemming from its ongoing phase 1b clinical trial of CAN-3110 (linoserpaturev) targeting recurrent glioblastoma. This...
Continue Reading
Supernus Pharmaceuticals Hits Record Stock Levels Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has achieved a remarkable milestone, as its stock recently surged to a 52-week high of $35.45. This significant increase showcases the company’s strong financial performance and growth prospects, creating a wave of optimism among investors. The stock has risen an impressive...
Continue Reading
